Correlative Study On The Expression Of ER And GPR30 In Cervical Carcinoma And Normal Cervical Tissue

Cervical cancer is a common female cancer and the most common gynecologic cancer. In China, cervical cancer has lower incidence rates than breast cancer and remains the second most common type of cancer and cause of cancer deaths among all types of cancer in women. Human papillomavirus (HPV) infection is central to the development of cervical neoplasia, which is a Long process. This process is also influenced by other factors.Estrogen is an important hormone, which is essential in the development and maintenance of female physiological function. Meanwhile, estrogen is also a risk factor of several female cancers. It has been indicated estrogen is the risk factor of breast cancer and endometrial cancer. But it is still unclear whether estrogen involves in the development of cervical cancer.Estrogen binds to estrogen receptors and then regulates cellular activity. Estrogen receptor (ER) has been widely known as the receptor of estrogen. Recently, another kind of estrogen receptor, G protein-coupled receptor 30 (GPR30) is gradually caught attentions. GPR30 protein is located in cellular membrane. It binds to estrogen, activates downstream EGF/MAPK pathway in the manner of non-genomic pathway. It has been known that GPR30 involves in the development of tumors. However, it is still unclear about the role of GPR30 in cervical cancer.Here, we collected tissue samples of cervical cancer and normal cervical as control, 37 cases respectively. Immunohistochemical staining was taken to indicate expression of ER and GPR30 in normal cervical tissues and cervical cancer tissues.In 37 normal cervical tissues, ER(+) is 100%, GPR30(+) is 16.2%; In 37 cervical cancer cases, ER(+) is 27%, GPR30(+) is 51.3%. The expression of GPR30 in cervical cancer is higher than that in normal tissues, while the expression of ER is significantly lower.We further analyzed the correlation between GPR30 expression and clinical significants of cervical cancer. GPR30 (+) is more common in post-menopausal patients compared with premenopausal patients. The lower positive rate of GPR30 was observed in poor differentiated tumor tissues. There is no obverse different in pathology types and metastasis of lymph node.Since GPR30 expression in cervical cancer is significantly higher, we suggest that that abnormal activation of GPR30 may promote cervical cancer. GPR30 may be a potential target for the treatment of cervical cancer. Meanwhile, post-menopausal patients relatives with high GPR30 expression, suggesting that HRT should be carefully used in this kind of patients.The main problem of this study remains. The abundance of cases is relatively limited. In further studies, the sample size should be expanded,with samples of cervical intraepithelial neoplasia (CIN) added.